Citigroup stock slides as Trump’s 10% credit-card rate cap plan rattles lenders ahead of earnings
12 January 2026
2 mins read

Citigroup stock slides as Trump’s 10% credit-card rate cap plan rattles lenders ahead of earnings

New York, January 12, 2026, 11:40 EST — Regular session

  • Citigroup shares fall mid-session as investors weigh a proposed 10% cap on credit-card interest rates
  • Analysts warn a cap would likely need Congress; banks say it could tighten credit access
  • Supreme Court decision keeps alive a fraud lawsuit tied to Citigroup’s Banamex unit

Citigroup Inc shares were down about 3.5% at $117.03 in late morning trading, after President Donald Trump called for a one-year cap on credit card interest rates at 10% starting Jan. 20 and gave no details on how companies would be made to comply. 1

The headline risk for Citi is simple: credit cards are a big consumer profit engine across the industry, and a hard ceiling would hit pricing on loans that carry no collateral. It also lands with bank earnings days away, when executives normally talk about credit quality, buybacks and how fast they can cut costs.

Some analysts doubt the idea can move quickly, or at all. UBS Global analysts said it would take an “Act of Congress,” while Seaport Research’s Bill Ryan said it was not surprising to see the idea revived as “affordability” has become a bigger political issue; JPMorgan analyst Vivek Juneja warned it could push consumers into “more expensive debt” outside the banking system. Credit card rates averaged 20.97% in November, the Federal Reserve’s consumer credit report showed, making the proposed cap a sharp cut from current pricing. 2

The selloff spread beyond Citi. The Financial Select Sector SPDR Fund was down about 1% and the SPDR S&P Bank ETF fell about 1.3%. Capital One slid nearly 7% and American Express dropped about 4%, while Visa and Mastercard were both lower by around 1% to 2%.

Citi also has a separate legal overhang. The U.S. Supreme Court declined to hear Citigroup’s appeal in litigation tied to the bankruptcy of Mexican oil-services firm Oceanografia, leaving in place a lower-court decision that revived the case. The plaintiffs, including bondholders, accuse Citi’s Banamex unit of enabling a fraud that caused more than $1 billion in losses; the appeal centered on whether bondholders can pursue claims under RICO, an anti-racketeering law that allows for triple damages. 3

Outside Wall Street, the politics are messy. An Associated Press report carried by ABC News cited researchers who estimated consumers could “save Americans $100 billion” a year if rates were capped, while banking groups argued a cap would curb credit lines for riskier borrowers and push them toward costlier alternatives. 4

The near-term risk for bulls is that the rate-cap idea stops being a headline and turns into a real legislative push, forcing lenders to tighten terms before any rule change hits. The counterpoint is that Washington talk fades fast, and bank results this week could pull attention back to earnings power and credit trends.

For Citi, the next hard catalyst is its fourth-quarter report on Wednesday. Investors will listen for any early read on card balances, delinquencies and the bank’s net interest margin — the spread between what it earns on loans and pays on funding — and whether executives see the policy noise turning into something they have to price for. 5

Stock Market Today

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
New York, Feb 7, 2026, 10:22 EST — Market closed. Eli Lilly and Company shares closed Friday up $37.34, or 3.7%, at $1,058.18. The move came as U.S. regulators sharpened their tone on “compounded” weight-loss drugs — pharmacy-made versions meant for shortages or special patient needs that have morphed into mass-market alternatives. The FDA said it would take action against telehealth firm Hims & Hers over a $49 pill it marketed as a Wegovy-like option, and Lilly said it “applauded” the agency’s action. 1 Why it matters now: obesity and diabetes medicines have become the growth engine for large drugmakers,
Saudi Aramco share price set for Sunday test after Tadawul ends market-making deal

Saudi Aramco share price set for Sunday test after Tadawul ends market-making deal

7 February 2026
Saudi Exchange approved Merrill Lynch KSA’s exit as market maker for Saudi Aramco, effective Feb. 8. Aramco shares closed at 25.60 riyals Thursday, down 0.06, with 22.1 million traded. The Tadawul index fell 1.3% as Brent crude dropped to $67.93. Aramco set March official selling prices at $2.10 above Argus for North America and $0.65 above ICE Brent for Western Europe.
Meta stock ends week down about 6% as Wall Street fixates on $135 billion AI capex

Meta stock ends week down about 6% as Wall Street fixates on $135 billion AI capex

7 February 2026
Meta closed down 1.3% Friday at $661.46, capping a 6.4% weekly drop as investors questioned heavy AI spending. Amazon and Alphabet also fell after outlining major capital outlays. Meta’s Instagram suffered a brief outage this week. Legal risks persist, with trials involving Meta set for next week in Los Angeles and New Mexico.
Visa stock slides on Trump credit-card rate cap talk as traders brace for bank earnings
Previous Story

Visa stock slides on Trump credit-card rate cap talk as traders brace for bank earnings

Broadcom stock pops early as traders brace for CPI and chip-demand readouts
Next Story

Broadcom stock pops early as traders brace for CPI and chip-demand readouts

Go toTop